The New York Times28d
Mets’ Nick Madrigal has big shoes to fill after last year’s utility man hit a high note
PORT ST. LUCIE, Fla. — Nick Madrigal doesn’t sing. He isn’t planning on performing a postgame summer concert. He’s not expecting to bust out a spirit-lifting catchphrase. “No ...
Yahoo Finance19d
Madrigal: Q4 Earnings Snapshot
WEST CONSHOHOCKEN, Pa. (AP) — WEST CONSHOHOCKEN, Pa. (AP) — Madrigal Pharmaceuticals Inc. (MDGL) on Wednesday reported a loss of $59.4 million in its fourth quarter. The West Conshohocken ...
The Motley Fool19d
Why Madrigal Pharmaceuticals Stock Is Soaring Today
Madrigal reported better-than-expected Q4 results. The company also announced positive new two-year data from a phase 3 study of its MASH drug Rezdiffra. Madrigal reported fourth-quarter revenue ...
Benzinga.com19d
Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis
Madrigal posted a Q4 loss of $2.71 per share, beating estimates, with sales of $103.22 million surpassing the $98.56 million consensus. Find out which stock just claimed the top spot in the new ...
MLB Rumors22d
Mets’ Nick Madrigal To Undergo MRI On Dislocated Left Shoulder
Nick Madrigal dislocated his left shoulder during today’s Spring Training split-squad game between the Mets and Nationals. In the first inning of the game, Madrigal (who was playing shortstop ...
Seeking Alpha19d
Madrigal Pharmaceuticals Q4 Earnings Review: Strong Quarter, Even Stronger Outlook
Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales up 66% to $103.3m. Despite a net loss of $466m in 2024, Madrigal's cash ...
CBSSports.com21d
Mets' Nick Madrigal: Moved to 60-day IL
Madrigal (shoulder) was placed on the 60-day injured list Monday. It was reported earlier in the day that Madrigal is expected to miss a significant period of time recovering from a fractured left ...
Benzinga.com18d
Decoding Madrigal Pharmaceuticals's Options Activity: What's the Big Picture?
High-rolling investors have positioned themselves bullish on Madrigal Pharmaceuticals MDGL, and it's important for retail traders to take note. \This activity came to our attention today through ...
The Washington Post18d
Mets infielder Nick Madrigal's fractured left shoulder could sideline him for the entire 2025 season
PORT ST. LUCIE, Fla. — New York Mets infielder Nick Madrigal could miss the entire 2025 season with a fractured left shoulder. Manager Carlos Mendoza told reporters Friday that Madrigal needs ...
Business Insider19d
Madrigal Pharmaceuticals Phase 3 data ‘encouraging,’ says UBS
Madrigal Pharmaceuticals (MDGL) reported Q4 results and provided a 2-year update from the open-label metabolic dysfunction-associated steatohepatitis compensated F4 arm of the Phase 3 MAESTRO ...
Yahoo Finance19d
Madrigal Q4 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
Madrigal Pharmaceuticals MDGL reported fourth-quarter 2024 loss of $2.71 per share, narrower than the Zacks Consensus Estimate of a loss of $4.12. In the year-ago quarter, the company had incurred ...